公开(公告)号：US20100081712A1

公开(公告)日：2010-04-01

申请号：US12624226

申请日：2009-11-23

Applicant: Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K31/7088 ,  C07H21/04 ,  A61P7/04

CPC classification number: C12N9/644 ,  A61K38/00 ,  C12Y304/21022

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Abstract translation: 本发明旨在将因子IX转化为具有增强的活性的分子，其为血友病B的替代疗法和基因治疗提供替代方案。使用重组技术，在位置86,277和338处置换的因子IX表现出比重组更好的凝血活性 野生型因子IX。

公开(公告)号：US20080200387A1

公开(公告)日：2008-08-21

申请号：US12030847

申请日：2008-02-13

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K38/16 ,  C07K14/00 ,  A61K31/711 ,  A61P7/00 ,  A61P35/04 ,  C07H21/04

CPC classification number: A01K67/0271 ,  A01K2207/15 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K38/00

Abstract: The present invention relates to an anti-angiogenic protein comprising a mutant kringle 1-5 (K1-5) fragment of plasminogen, wherein a set of mutation position is selected from the group consisting of positions 227, 284 and 470 of SEQ ID NO. 6, and wherein the position 227 is replaced with an amino acid residue without forming glycosylation, the position 284 is replaced with an amino acid residue without forming glycosylation, and the position 470 is replaced with Arg. The present invention also provides a nucleic acid having a sequence encoding said anti-angiogenic protein. The invention further relates to a pharmaceutical composition for inhibiting angiogenesis comprising said anti-angiogenic protein or said nucleic acid. The present invention also provides a method for treatment of an angiogenesis associated disease or disorder, comprising administering to a patient in need of such treatment an effective amount of said pharmaceutical composition.

Abstract translation: 本发明涉及一种抗血管生成蛋白，其包含纤溶酶原的突变体kringle 1-5（K 1〜5-N个）片段，其中一组突变位置选自位置227， 284和470的SEQ ID NO： 6，并且其中位置227被氨基酸残基替代而不形成糖基化，位置284被氨基酸残基替代而不形成糖基化，并且位置470被Arg取代。 本发明还提供了具有编码所述抗血管生成蛋白的序列的核酸。 本发明还涉及包含所述抗血管生成蛋白或所述核酸的用于抑制血管生成的药物组合物。 本发明还提供了治疗血管生成相关疾病或病症的方法，其包括对需要这种治疗的患者施用有效量的所述药物组合物。

公开(公告)号：US20080039484A1

公开(公告)日：2008-02-14

申请号：US11836159

申请日：2007-08-09

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K31/485 ,  A61P9/00

CPC classification number: A61K31/485

Abstract: The present invention relates to a method for preventing or treating a cardiovascular disease.

Abstract translation: 本发明涉及一种预防或治疗心血管疾病的方法。

公开(公告)号：US20070203164A1

公开(公告)日：2007-08-30

申请号：US11361589

申请日：2006-02-24

Applicant: Chuan-Chi Chiang ,  Hui-Pin Su ,  Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Chuan-Chi Chiang ,  Hui-Pin Su ,  Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K31/485

CPC classification number: A61K31/485 ,  Y10S514/859

Abstract: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-α, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.

Abstract translation: 本发明涉及一种提供杀菌剂或抑菌剂的方法，特别是用于治疗由细菌感染引起的疾病。 该方法包括给予需要这种治疗的患者治疗有效量的右美沙芬或纳洛酮或其药学上可接受的盐或类似物的化合物。 该化合物应用于患者的皮肤或粘膜表面。 本发明还涉及一种治疗由巨噬细胞抑制TNF-α，IL-6或MCP-1分泌引起的炎症的方法，包括给予需要这种治疗的患者治疗有效量的NADPH氧化酶抑制剂。

公开(公告)号：US20060148695A1

公开(公告)日：2006-07-06

申请号：US11149378

申请日：2005-06-09

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K48/00 ,  A61K38/18

CPC classification number: A61K48/00 ,  A61K38/366

Abstract: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.

Abstract translation: 本发明涉及促进血管发生的组合物，用于控制细胞的DNA合成和用于控制细胞的趋化运动性。 本发明还涉及一种治疗缺血性疾病的方法。

公开(公告)号：US20240092861A1

公开(公告)日：2024-03-21

申请号：US18447229

申请日：2023-08-09

Applicant: Chao-Han LAI ,  Jwu-Lai YEH ,  Hua-Lin WU ,  Shang-En HUANG

Inventor： Chao-Han LAI ,  Jwu-Lai YEH ,  Hua-Lin WU ,  Shang-En HUANG

IPC: C07K14/705 ,  A61P19/10

CPC classification number: C07K14/7056 ,  A61P19/10 ,  C07K2319/03

Abstract: CD93 functional domains for use in treating osteoporosis. A method of alleviating, reducing, suppressing, and/or treating an osteoclast-related bone disease is disclosed. The method comprises administering a therapeutically effective amount of an isolated recombinant protein comprising an amino acid sequence that is at least 80% identical to human Cluster of Differentiation 93 protein domain 1 to a subject in need thereof, the recombinant protein lacking amino acid residues 1 to 21, transmembrane and cytoplasmic domains of the human CD93 (SEQ ID NO: 3) and having a total length of no more than 559 amino acid residues. In one embodiment, the osteoclast-related bone disease is at least one selected from the group consisting of osteoporosis, postmenopausal osteoporosis, osteopenia, bone loss, inflammatory bone loss, and any combination thereof. In another embodiment, the recombinant protein comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

公开(公告)号：US20130190243A1

公开(公告)日：2013-07-25

申请号：US13733902

申请日：2013-01-04

Applicant: Chao-Han LAI ,  Guey-Yueh Shi ,  Hua-Lin Wu

Inventor： Chao-Han LAI ,  Guey-Yueh Shi ,  Hua-Lin Wu

IPC: A61K38/36

CPC classification number: A61K38/366

Abstract: A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm.

Abstract translation: 公开了用于药理学预防和抑制主动脉瘤发展的方法。 该方法包括向有需要的受试者施用治疗有效量的重组血栓调节素。 重组血栓调节蛋白阻止主动脉瘤的形成和/或延缓进展。

公开(公告)号：US08293231B2

公开(公告)日：2012-10-23

申请号：US12856556

申请日：2010-08-13

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K38/48

CPC classification number: A61K48/00 ,  A61K38/366

Abstract: A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2.

Abstract translation: 公开了一种治疗从血管发生中受益的缺血的方法。 该方法包括向有需要的受试者施用组合物，其包含：a）治疗有效量的人血栓调节素片段; 和b）药学上可接受的载体; 其中所述片段包含SEQ ID NO：2的氨基酸Ala242至Ser515。

公开(公告)号：US20100113568A1

公开(公告)日：2010-05-06

申请号：US12261736

申请日：2008-10-30

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K31/7088 ,  C12Q1/68

CPC classification number: A61K38/366 ,  G01N33/86 ,  G01N2333/7452

Abstract: A method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of nucleotide sequence encoding N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues; and a method of detecting cancer cells, Gram-negative bacteria or LPS which over-express the Lewis Y antigen in a sample from a subject.

Abstract translation: 一种用于结合受试者的Lewis Y抗原的方法，包括向受试者施用有效量的编码血栓调节蛋白（TMD1）的N-末端凝集素样结构域的核苷酸序列或其类似物; 以及检测来自受试者的样品中过表达Lewis Y抗原的癌细胞，革兰氏阴性细菌或LPS的方法。